NORTHLAND Wins Three Awards in the 5th Wabe New Third Board Year-End Selection
On December 24, 2020, the "5th Wabe New Third Board Leading Enterprises Annual Conference & Wabe Golden Stock Awards Ceremony," jointly hosted by Wabe.com and the Wabe New Third Board Research Institute, was successfully held at the Crowne Plaza Hotel You Tang in Beijing. This year's conference was themed "New Starting Point, New Journey, New Future," and focused on exploring hot topics such as new opportunities in the New Third Board under the integrated multi-level capital market, investment logic for the Select Tier, and how to prepare for a potential transfer to the main board listing.

At the meeting, the winners of the “2020 Wabe New Third Board Year-End Awards” were announced, and a grand awards ceremony was held. Our company was delighted to receive three awards: “2020 Outstanding Chairman of the New Third Board,” “2020 Leading Enterprise in the Medical and Healthcare Industry,” and “2020 Secretary of the Board Contribution Award.” As a representative of the company, our Chairman Xu Songshan was invited to participate in the roundtable forum titled “How Small and Medium-Sized Enterprises Can Prepare for Listing on a Higher Board,” where he shared insights into the benefits his company has gained since listing on the New Third Board and offered suggestions for further reforming the New Third Board.

This year, the Wabei New Third Board Year-End Awards featured four categories: Outstanding Chairman of the New Third Board, Leading Enterprise of the New Third Board, Secretary of the Board Contribution Award, and Golden Stock Award. A total of 109 listed companies participated in the评选. After online voting and review by the judging panel, our company was honored with three awards, fully demonstrating the capital market’s attention to and high recognition of our company.
Standing at a new starting point on the Select Tier, the company will carry forward the past while forging ahead, live up to its mission, accelerate the development of new drugs, and repay the trust of our investors and society with outstanding performance.



